Premium
Immune status of patients with haemophilia A before exposure to factor VIII : first results from the HEMFIL study
Author(s) -
Jardim Letícia L.,
Chaves Daniel G.,
SilveiraCassette Amanda C. O.,
Simões e Silva Ana Cristina,
Santana Marcio P.,
Cerqueira Monica H.,
Prezotti Alessandra,
Lorenzato Claudia,
Franco Vivian,
Bom Johanna G.,
Rezende Suely M.
Publication year - 2017
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14799
Subject(s) - interleukin 10 , chemokine , medicine , immunology , haemophilia , immune system , interleukin 8 , platelet , interleukin 4 , interleukin , inflammation , eotaxin , cytokine , pediatrics
Summary Previous cross‐sectional studies showed that some patients with haemophilia A ( HA ) without inhibitor presented a pro‐inflammatory profile during factor VIII ( FVIII ) replacement therapy. Furthermore, an anti‐inflammatory/regulatory state was described in HA patients after inhibitor development. However, no study investigated the levels of these biomarkers before exposure to exogenous FVIII . This study investigated the immunological profile of previously untreated patients ( PUP s) with HA in comparison with non‐haemophiliac boys. A panel of chemokines and cytokines was evaluated in the plasma of 40 PUP s with HA and 47 healthy controls. The presence of microparticles was assessed in the plasma of 32 PUP s with HA and 47 healthy controls. PUP s with HA presented higher levels of CXCL 8 ( IL 8), IL 6, IL 4, IL 10, IL 2, IL 17A ( IL 17), and lower levels of CXCL 10 ( IP ‐10) and CCL 2 ( MCP ‐1) than the age‐matched healthy controls ( P < 0·05). We also observed higher levels of microparticles derived from endothelium, erythrocytes, platelets, leucocytes, neutrophils, and T lymphocytes in patients in comparison with controls ( P < 0·05). Compared with controls, PUP s with HA presented a distinct immunological profile, characterized by a prominent pro‐inflammatory status that appears to be regulated by IL 4 and IL 10.